O1‐04‐07: Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18‐month international multi‐center phase 3 trial-Reference-Cited by-同舟云学术

O1‐04‐07: Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18‐month international multi‐center phase 3 trial

Published:2009-07 Issue:4S_Part_3 Volume:5 Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Wilcock Gordon K.¹,Black Sandra E.²,Balch Alfred H.³,Amato David A.³,Beelen Andrew P.³,Schneider Lon S.⁴,Green Robert C.⁵,Swabb Edward A.³,Zavitz Kenton H.³

Affiliation:

1. University of OxfordOxfordUnited Kingdom

2. Sunnybrook Health Sciences CentreUniversity of TorontoTorontoONCanada

3. Myriad PharmaceuticalsSalt Lake CityUTUSA

4. University Of Southern California Keck School of MedicineLos AngelesCAUSA

5. Boston University School of MedicineBostonMAUSA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2009.05.220

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammation: A Major Target for Compounds to Control Alzheimer’s Disease;Journal of Alzheimer's Disease;2020-08-18

2. A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease;Frontiers in Immunology;2020-03-31

3. Mitochondria-Targeted Nanoparticles;Alzheimer's Disease Theranostics;2019

4. C-Terminal Fragment, Aβ39–42-Based Tetrapeptides Mitigates Amyloid-β Aggregation-Induced Toxicity;ACS Omega;2018-08-28

5. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer's disease;Journal of Pharmacy and Pharmacology;2017-10-16